Amir

Based on positive data from a Phase IIb pivotal study suggesting that P2B001 may offer effective therapy with minimal side effects for early stage Parkinson’s Disease (PD) patients, Pharma Two B initiated a multinational Phase III clinical trial Rehovot, Israel – February 6th, 2018 – Pharma Two B Ltd., a privately held company developing innovative …

First Patients Dosed in Phase III Multi-center, Multinational Study to Determine the Efficacy, Safety and Tolerability of P2B001 in Patients with Early Stage Parkinson’s Disease Read More »

REHOVOTH, Israel, February 27, 2017 — Pharma Two B Ltd., a privately held biopharmaceutical company focused on developing treatments for Parkinson’s disease, announced today it has completed its third round of financing. The $30MM funding round was led by Israel Biotech Fund (IBF) which identified the company, led the due diligence, and syndicated with leading US and Israeli biotechnology investors, including aMoon and JVC. Current investors, including JK&B and Generali Financial Holdings FCP-FIS SF2 participated in this round as well. Mr. Jeff Kindler, a member of Israel Biotech Fund’s Venture Advisory Team, will join Pharma Two B’s Board of Directors. Mr. Kindler is the former CEO and chairman of Pfizer.